Background and aims Molnupiravir is a newer oral antiviral drug that has recently received
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …

Abstract Background Starting in November 2020, the US Food and Drug Administration
(FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing …

Background The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in
hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The …

We report herein an alternative method for the synthesis of seleno-dibenzocycloheptenones
and seleno-spiro [5.5] trienones through the radical cyclization of biaryl ynones in the …

Abstract Purpose Coronavirus disease 2019 (COVID‐19) is associated with
hypercoagulability and increased thrombotic risk. The impact of prehospital antiplatelet …

Fibromyalgia (FM) is a complex disease with an uncertain aetiology and intricate
pathophysiology. Although its genesis is not fully explained, potential environmental factors …

Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …

Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating …

Objective: We assessed the efficacy of colchicine in COVID-19 patients through a systematic
review. Methods: Six databases were searched until March 2022 for studies assessing …

Abstract Background Anti‐SARS‐CoV‐2 S antibodies prevent viral replication. Critically ill
COVID‐19 patients show viral material in plasma, associated with a dysregulated host …